Increased CCL2 transcripts have been observed in the lamina propria of IBD patients, and CCL2 serum levels have been associated with treatment failure of anti-TNF-α and anti-p40 agents in CD [67]. This evidence concerns the gene CCL2 and inflammatory bowel disease.